Opko Health Stock Set to Open Lower After Trial Suspended

The healthcare stock is heavily shorted

Feb 1, 2019 at 9:13 AM
facebook twitter linkedin


The shares of Opko Health Inc. (NASDAQ:OPK) are down 3.8% in electronic trading, after the Florida-based diagnostics firm said its suspending a mid-stage trial studying OPK-88004, a selective androgen receptor modulator (SARM) used on patients with benign prostatic hyperplasia. This is offsetting news the Food and Drug Administration (FDA) approved the company's prostate specific antigen test.

Heading into today's trading, OPK stock had made strides off its late-December low of $2.34 -- up 57.3% to last night's close at $3.68. However, this rally ran out of steam near $3.90, a level that's contained the security since last October. Plus, the shares remain well off their July 17 annual high of $6.40.

Analysts have been slow to initiate coverage on Opko Health stock. Just two brokerages follow the stock, with one maintaining a "strong buy," and the other a tepid "hold." The average 12-month price target, meanwhile, sits all the way up at $10 -- territory the security hasn't charted since late 2016.

Short sellers will certainly be cheering, should today's price action pan out. While OPK stock is likely headed to the short-sale restricted list today, these bearish bettors control 59.3 million shares, representing 19.2% of the equity's float, or 12.5 times the average daily pace of trading.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners